You might also like
STERIS is a leading global provider of products and services focused on infection prevention, supporting patient care through innovative healthcare and life science solutions. The company operates in three main business segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences . STERIS offers a comprehensive range of products and services, including infection prevention consumables, capital equipment like sterilizers and surgical tables, and services such as equipment maintenance and instrument repair . The company has divested its Dental segment to focus on core markets in healthcare, pharma, and MedTech .
- Healthcare - Offers a comprehensive range of products and services for healthcare providers, including infection prevention consumables, capital equipment like sterilizers and surgical tables, and services such as equipment maintenance and instrument repair .
- Applied Sterilization Technologies (AST) - Provides contract sterilization and laboratory testing services for medical device and pharmaceutical manufacturers, offering a technology-neutral approach from testing through sterilization .
- Life Sciences - Supports biopharmaceutical and medical device research and manufacturing facilities with products like pharmaceutical detergents, sterilizers, and maintenance services .
- With the AST segment no longer expected to exit the year at double-digit revenue growth and margins impacted by labor and energy costs, what specific strategies are you implementing to improve AST's growth trajectory and profitability in the face of these challenges?
- Given the anticipated flat to slightly down Healthcare capital equipment revenue for fiscal 2025 due to timing of shipments and difficult fourth quarter comparisons, how confident are you that recurring revenue outperformance can fully offset this decline, and what steps are you taking to drive capital equipment growth?
- The Life Sciences segment is now expected to have flat revenue for the year, with declines in capital equipment sales partially mitigated by consumables. What are the underlying factors contributing to the decline in Life Sciences capital equipment, and how do you plan to address this weakness?
- Labor and energy costs continue to pressure margins, particularly in AST, and you mentioned the inability to immediately pass on increased energy costs to customers. How are you planning to manage these costs, and when do you anticipate seeing margin improvement as a result?
- You reported a one-time loss on a capital equipment order in your med-x business unit that negatively impacted AST margins. Can you provide more details on what led to this loss and what measures you're putting in place to prevent similar issues in the future?
Competitors mentioned in the company's latest 10K filing.
- 3M: Competitor in product offerings.
- Baxter: Competitor in product offerings.
- Boston Scientific: Competitor in product offerings.
- Belimed: Competitor in product offerings.
- Fortive: Competitor in product offerings.
- Getinge: Competitor in product offerings.
- Karl Storz: Competitor in product offerings.
- Olympus: Competitor in product offerings and service lines.
- Ruhof: Competitor in product offerings.
- SteelCo: Competitor in product offerings.
- Stryker: Competitor in product offerings.
- Skytron: Competitor in product offerings.
- Wassenburg: Competitor in product offerings.
- Agiliti: Competitor in service lines.
- BBraun: Competitor in service lines.
- Crothall: Competitor in service lines.
- Pentax: Competitor in service lines.